Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Recommendations

Info

220 Applying Pharmacogenomics in Therapeutics61. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderatorsof medication response: A double-blind placebo-controlled study. Arch GenPsychiatry 2007;64:1069–1077.62. Oslin DW, Berrettini WH, O’Brien CP. Targetting treatments for alcohol dependence:The pharmacogenetics of naltrexone. Addict Biol 2006;11:397–403.63. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotinemetabolic rate predicts successful smoking cessation with transdermal nicotine:A validation study. Pharmacol Biochem Behav 2009;92:6–11.64. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotinemetabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. ClinPharmacol Ther 2006;79:600–608.65. Sturgess JE, George TP, Kennedy JL, Heinz A, Muller DJ. Pharmacogenetics of alcohol,nicotine and drug addiction treatments. Addict Biol 2011;16:357–376.66. Hresko A, Haga S. Insurance coverage policies for personalized medicine. J Pers Med2012;2:201–216.67. De Leon J. Pharmacogenomics: The promise of personalized medicine for CNSdisorders. Neuropsychopharmacology 2009;34:159–172.
9 ApplyingPharmacogenomicsin the Therapeuticsof Pulmonary DiseasesWei Zhang and Jason X.-J. YuanCONTENTSKey Concepts.......................................................................................................... 221Introduction.............................................................................................................222General Pharmacogenetic and Pharmacogenomic Approaches..............................223Applying Pharmacogenomics to Pulmonary Disorders..........................................224Chronic Obstructive Pulmonary Disease...........................................................224Brief Background..........................................................................................224Therapy for COPD........................................................................................225Genetics and Pharmacogenetics of COPD....................................................226Asthma...............................................................................................................227Brief Background..........................................................................................227Therapy for Asthma.......................................................................................228Genetics and Pharmacogenetics of Asthma..................................................229Pulmonary Hypertension....................................................................................230Brief Background..........................................................................................230Therapy for Pulmonary Hypertension........................................................... 231Genetics and Pharmacogenetics of Pulmonary Hypertension....................... 232Conclusions............................................................................................................. 233Thoughts for Further Consideration........................................................................ 233Study Questions......................................................................................................234References...............................................................................................................234KEY CONCEPTS• Pharmacogenetic and pharmacogenomic studies aim to elucidate geneticdeterminants for drug response, a complex phenotype.• Responses to therapeutics may be affected by various genetic and nongeneticfactors.• Several pulmonary disorders, such as chronic obstructive pulmonarydisease (COPD), asthma, and pulmonary hypertension, have been under221
Page 1:
ApplyingPharmacogenomicsin Therapeu
Page 5 and 6:
ApplyingPharmacogenomicsin Therapeu
Page 7:
DedicationWe dedicate this book to
Page 10 and 11:
viiiContentsChapter 10 Pharmacogeno
Page 13 and 14:
EditorsXiaodong Feng, PhD, PharmD,
Page 15 and 16:
ContributorsWeiguo Chen, PhDDepartm
Page 17 and 18:
1Concepts inPharmacogenomics andPer
Page 19 and 20:
Concepts in Pharmacogenomics and Pe
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
2Principles ofPharmacogeneticBiotec
Page 51 and 52:
Principles of Pharmacogenetic Biote
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65:
Page 68 and 69:
52 Applying Pharmacogenomics in The
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 91 and 92:
4 ApplyingPharmacogenomicsin Drug D
Page 93 and 94:
Applying Pharmacogenomics in Drug D
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
5 Pharmacogenomicsand Laboratory Me
Page 113 and 114:
Pharmacogenomics and Laboratory Med
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157:
Page 160 and 161:
144 Applying Pharmacogenomics in Th
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187: 170 Applying Pharmacogenomics in Th
Page 217 and 218: 8Clinical Applicationsof Pharmacoge
Page 219 and 220: Pharmacogenomics of CNS Disorder Tr
Page 235: Pharmacogenomics of CNS Disorder Tr
Page 239 and 240: Applying Pharmacogenomics in the Th
Page 259 and 260: 10Pharmacogenomics andAlternative M
Page 261 and 262: Pharmacogenomics and Alternative Me
Page 287 and 288:
11 PharmacoeconogenomicsA Good Marr
Page 289 and 290:
Pharmacoeconomics of Pharmacogenomi
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
5’3’5’3’ 5’3’ 5’3’3
Page 305 and 306:
1 2 3 4 5Vysis LSI BCR/ABL + 9q34 t
Page 307:
BIOMEDICAL SCIENCEApplying Pharmaco
show all

Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Create successful ePaper yourself

Delete template?

Save as template?